203 related articles for article (PubMed ID: 12604695)
1. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
2. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
5. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
6. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.
Johnson-Davis KL; Truong JG; Fleckenstein AE; Wilkins DG
J Pharmacol Exp Ther; 2004 May; 309(2):578-86. PubMed ID: 14747615
[TBL] [Abstract][Full Text] [Related]
7. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
Hanson GR; Sandoval V; Riddle E; Fleckenstein AE
Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent effects of methamphetamine on VMAT-2.
Rau KS; Truong JG; Wilkins DG; Fleckenstein AE; Hanson GR
Ann N Y Acad Sci; 2006 Aug; 1074():154-9. PubMed ID: 17105913
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
Ugarte YV; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Jul; 472(3):165-71. PubMed ID: 12871750
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
Truong JG; Newman AH; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
[TBL] [Abstract][Full Text] [Related]
13. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2006 Jul; 155(1):109-15. PubMed ID: 16480775
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
Volz TJ; Hanson GR; Fleckenstein AE
Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice.
Ji J; McDermott JL; Dluzen DE
J Neuroendocrinol; 2007 Sep; 19(9):725-31. PubMed ID: 17680888
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
17. Differential regional effects of methamphetamine on dopamine transport.
Chu PW; Seferian KS; Birdsall E; Truong JG; Riordan JA; Metcalf CS; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2008 Aug; 590(1-3):105-10. PubMed ID: 18599036
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.
Bourque M; Liu B; Dluzen DE; Di Paolo T
Biochem Pharmacol; 2007 Nov; 74(9):1413-23. PubMed ID: 17825264
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
Volz TJ; Fleckenstein AE; Hanson GR
Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine rapidly decreases vesicular dopamine uptake.
Brown JM; Hanson GR; Fleckenstein AE
J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
